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Sclerotic ApoE’- mice, and that chronic blockade of 5HT,, and 5HT, receptors 
improves ischemic outcome of PAD but does not reduce the progression of atherosclero- 
sis. 
1180-118 Effect of CC-Chemokines (MCP-1) in a Novel Porcine 
Model of Peripheral Vascular Disease 
Michiel Voskuil, Niels Van Royen. Imo Hoefer. Brian Guth. Randolph &idler, Klaus 
Scheffler, Sebastian Grundmann, Juergen Hennig, Wolfgang Schaper. Christoph Bode, 
Jan J. Pick, Ivo R. Buschmann, Academic Medical Center, Amsterdam. The Netherlands 
Background: For an appropriate extrapolation to patients with peripheral arterial obstruc- 
tive disease ws tested the efficacy of monocyie chemoattractant protein 1 (MCP-1) treat- 
ment in a novel porcine hind limb ligation model. Both flow and pressure parameters 
were used lo evaluate changes after treatment with MCP-1. 
Methods: In 36 minipigs, a ligation of the femoral artery was performed, distal to the bifur- 
cation of the deep femoral artery An infusion catheter was inserted proximal to the liga- 
tion Site to ensure a first-pass effect of the compound across the collateral vascular bed. 
This catheter was connected lo an external infusion pump. Animals were examined after 
acute ligation (n = 4), after 48 hours (n=13) or two weeks (n=lO) treatment wth 2bg/h 
MCP-1 (BIWH 3) and were compared to control animals with PBS (n=9). In the terminal 
experiment resting flow and pressure in the iliac artery as well as peripheral arterial pres- 
sures were assessed. Arterial perfusion pressure was controlled using a pump driven 
extracorporal circulation that was inserted in the abdominal aorta. Vascular conductance 
was determined during maximal vasodilatation. The formation of collateral arteries were 
visualized using both in viva and post-mortem anglography. 
Results: Resting blood flows in the leg were 25%, 53%, 81% and 81% of the contra lat. 
era1 leg after acute ligation, after two weeks infusion of PBS, and after 40 hours and two 
weeks of treatment with MCP-1 (p < 0.05 for PBS compared to both MCP-1 groups). Dis- 
tal pressures were 46%. 73%, 75% and 76% acutely after ligation, after two weeks infu- 
sion of PBS or 48 hours and two weeks treatment with MCP-1, respectively (p = NS for 
PBS compared to both MCP-1 groups). Finally, collateral conductance was 158 * 97 ml/ 
minlmmHg after acute ligation, 645 f 346 ml/minlmmHg after two weeks of infusion with 
PBS, and 1070 f 530 and 1158 I 535 ml/min/mmHg after 48 hours and two weeks treat- 
ment with MCP-1, respectively (p < 0.05). 
Conclusions: Intra-arterial infusion of CC-chemokines results in modulation of the pro- 
cess of arteriogenesis in this novel large animal model. Perfusion of the occluded leg 
was improved using a 48 hours infusion of MCP-1 and remained unchanged after 2 
weeks of treatment 
1180-119 Intravascular Ultrasound Molecular Imaging of ICAM-1, 
VCAM-1, Fibrinogen, and Fibrin in a Yucatan Miniswine 
Model of Atherosclerosis 
Andrew J. Hamilton, Shao-Lina Huanq, Mark Rabbat, Drew Warnick, Ashwin Nagara], 
Bonnie J. Kane, Melvin Klegerman, Robert C. MacDonald, David D. McPherson, 
Northwestern University, Chicago and Evanston, IL, EchoDynamIcs, Inc., College Park, 
MD 
# 
Background: Targeted echogemc immunoliposomes (ELIP) for ultrasonic detection and 
staging of active molecular components of endothelium (ENDO) and atherosclerosis 
(ATH) have been developed. Our purpose was to determine the extent and specificity of 
ELIP ATH component highlighting in viva. 
Methods: In 5 ATH Yucatan miniswine, END0 was denuded from one femoral and one 
carotid artery and the animals fed a high cholesterol diet for 2 months to create early and 
late stage ATH. Femoral and carotid arteries were imaged using intravascular ultrasound 
(IVUS) prior to and 5 minutes post ELIP injection (5mg dose). Anti-ICAM, anti-VCAM, 
anti-fibrin, anti-fibrinogen conjugated ELIP were used depending on the degree of ATH. 
A blinded observer determined if each segment of the arterial END0 was enhanced. The 
IVUS images were reconstructed in 3D and vidaodensitometric analysis of the ENDO- 
blood mterface used to determine the mean gray scale (MGS) change in enhanced and 
non-enhanced segments. lmmunohistochemistry was used to confirm molecular compo- 
nent expression. 
Results: Six arteries had segments idenbfled as enhanced. 12 arteries had no enhance- 
ment of segments. lmmunohistochemical staining confirmed the expression/lack of 
expression of respective molecular targets in all th& observer-identified segments. 
Atheroma Enhancement MGS change ELlPvs.Saline 
Conjugated ELIP Unconjugated ELIP 
Positive 40.4 * 19% * 1.4 * 3.9% 
Negative 0.9 * 7.5% 3.4 f 5.8% 
* pqO.05 vs. Saline 
Conclusion: ELIP specifically enhance atheroma component?.. This allows for better 
characterization of the type and extent of active molecular ATH components and may 
allow for more directed therapy. 
# 
1180-152 Oxidative Damage and Repair System in Spinal Cord 
lschemia and Reperfusion Injury 
Roxian Lin, Glen Roseborough, Yafong Dong, G. Melville Williams, Chiming Wei, 
University of Maryland, Baltimore, MD, Johns Hopkins University, Baltimore, MD 
Spinal cord injury following a successful operation on thoracic and thoracoabdominal 
aneurysms is a disastrous complication in humans. It is believed that the cause of spinal 
cord dysfunction is ischemia from hypoperfusion during cross-clamping. Research has 
also indicated other factors as mediators of delayed cell death after central nervous sys- 
tem ischemia, including free radical production and apoptosls. The reactive oxygen spe- 
cies (ROS) plays a critical role in the pathogenesis of ischemia-reperfusion injury. 
Therefore, the current study was designed to investigate the DNA damage such 8-0xoG 
generation and its relationship with apoptosis as well as DNA repair enzyme exprsss~on 
in spinal cord with ischemia-reperiusion injury. Spinal cords of rabbits were removed at 1, 
3, 6, 24, 48 hours after 30 min of infrarenal aorhc occlusion. DNA damage was deter- 
mined by 8-0xoG staining. The expression and localization of DNA repair enzymes such 
as MYH, OGGl and MSH2 were studied by Western blot analysis and immunohis- 
tochemical staining. The levels of apoptosis and apoptosls-related gene expression 
(such as caspase-3) were determined by TUNEL study and Western blotting. Neurologi- 
cal functional score was investigated during spinal cord ischemia-reperfusion mjury. DNA 
damage such as 8.0xoG level was significantly increased from 1-hr lo 6.hr after reperfu- 
Sion in ischemic spinal card. The levels of hMYH, hOGG1 and hMSH2 were markedly 
increased at 6.hr after reperfusion. Furthermore, the peak level of TUNEL was found at 
48.hr after reperfusion in spinal cord. lmmunoreactlvity of caspase 3 was induced at 6-hr 
to 24.hr after reperfusion in ischemic spinal cord. The increased 8.oxoG level was corre- 
lated with neurological score in rabbits with spinal cord injury. The current study demon- 
strated that the DNA damage-repair system may plays an important mechanism in 
apoptosis and pathophysiological changes in spinal cord during ischemia-reperfusion 
injury. 
1180-153 Percutaneous Aortic Valve Replacement in the Beating 
Heart: First Animal Results 
Markus Ferrari, Gerhard Hellige, Markus Schlosser, lnes Frerichs, Eckehardt Mueller, 
Volker Guyenot, Gerd Eisold. Hans R. Figulla, Friedrich-Schiller-University, Jew, 
Germany, Fraunhofer Institute, Jena. Germany 
Introduction: Due lo increasing number of elderly patients with relevant co-morbidity 
there is need for a non-invasive technique of aortic valve replacement. Therefore, we 
evaluated the feasibility of transvascular aoriic valve replacement in animal experiments. 
Methods: Pulmonary valves from pigs were fixed in a self-expanding stent after low- 
pressure fixation in glutaraldehyde solution for 72 hours. The Stent (6 cm in length) con- 
taining the biologiocal valve in its proximal part was implanted in 3 pigs (68.104 kg) by 
means of a 25F catheter via the lefi subclavian artery by guidance of fluoroscopy and 
trams-oesophageal ultrasound (TEE). During stent deployment the original aortic valve 
was pushed against the aor?ic wall. 
Results: It was possible to replace the aortic valve I” the beating heart without any com- 
plication or even relevant drops in blood pressure. Under standard hemodynamic moni- 
toring we infused dopamine with doses of 5 pg/kg/min., 10 pglkglmin., and 15 pglkglmin. 
Cardiac output increased from 3.8 to 9.7 llmin., and the blood pressure rose from 96 I54 
mmHg to 138 / 111 mmHg respectively. The maximal peak to peak pressure gradient 
across the valve carrying stent increased from O-2 mmHg at rest to 5-8 mmHg under infu- 
sion of dopamine. Peak aortic flow increased from 0.8 m/s to 1.7 m/s measured by TEE. 
No relevant aortic insufficiency of the implanted valve was observed by Doppler flow 
analysis. All pigs were sacrificed afier 5 hours post transvascular aortic valve replace- 
ment. The chest was opened and the left ventricle and the ascending aorta were care- 
fully inspected. There were no signs of malfunction of the implant, or of damage of the 
aortic vessel wall. 
Conclusion: This study proves the feasibility of trans.vascular aortic valve replacement 
in the beating heart. Further diameter reduction of the implantation-catheter-device, and 
chronic animal experiments are on its way. 
1180-l 54 Convergence and Stabilization of Cellular Proliferation 
Into Steady State Over the Permanent Arterial Filtration 
Struts of the Diverter: A Novel Percutaneous Device for 
Protection Against Embolic Stroke 
Dagan Harris, Jonathan Lear. Yaron Assaf, Boaz Nishri, Orna Oz, David Tanne.m 
grad. Ofer Yodfat, MindGuard Medical Devices Ltd., Caesarea, Israel 
Purpose: To prove the long term patency of a novel filtering device (the Diverter) percuta- 
neously implanted at the carotid bifurcation. The device redirects emboli away from the 
internal into the external carotid artery and thus may prevent embolic Stroke of central 
source such as afib. We have previously shown that the diverter, which is a fine struc- 
tured stem like mesh is capable of arterial blood filtration up to 4 months. Our aim was to 
determine cellular proliferation rates over the filtering area. 
Methods: Diverters (n=lO) composed of fine wire meshes were successfully implanted, 
by percutaneous approach into the swme illio-femoral bifurcation. The bifurcations were 
harvested for evaluation at short, mid and long-term follow up periods (1, 3 and 23 
weeks) post implantation. The animals were injected with BrdU (40mg/kg) 24h and lh 
prior sacrifice. The filtering parts were embedded by paraffin and stained by hematoxilin 
(for total cell counting) and lmmunohistolabeling using an anti-BrdU monoclonal anti- 
body. Each filtering parl was tested at 4 different microscopical fields using morphometrl- 
cal software. Proliferation rate was measured as the percent of BrdU stained vs. the total 
number of cells at the filtering area. 
Results: Flow patency of the Diverter was confirmed prior to anlmal sacrifice by angiogra- 
phy and Doppler ukrasonography. Microscopical evaluation and morphometry showed 
that most of the filtered area of the 10 specimens remained patent, and the percent of 
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BrdU labeled cells 18.72a7.25, 12.80*4.58 and 0.74kO.56 at I, 3 and 23 weeks respec- 
tively which correspond to the proliferation rate, was negligible after 23 weeks. 
Conclusions: The cellular growth over the filtering struts of the Diverter converges and 
reaches steady state within 6 months. Permanent arterial filtration by percutaneous 
Implantation of the fine wire based Diverler is feasible and free of risk of cellular over- 
growth and lumen obliteration. Our preliminary findings give hope for a new promising 
strategy for preventing embolic stroke. The approach would be particularly useful in eld- 
erly patients with chronic atrial fibrillation and contra-indications to anti-coagulation. 
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1181-120 Statins Promote Systemic Antioxidant Effects Through 
Specific Inflammatory Pathways 
Mehdi H. Shishehbor, Marie-Luise Brennan, Ronnier J. Aviles, Dennis L. Sprecher, 
Stanley L. Hazen. The Cleveland Clinic Foundation, Cleveland, OH 
Background: Formation of nitric oxide-derived oxidants and oxidative cross-linking of pro- 
teins both serve as potential mechanisms linking inflammation to development of athero- 
sclerosis. Nitrotyrosine (NOPTyr) and dityrosine (diTyr), specific molecular fingerprints of 
distinct oxidation pathways that convert LDL into an atherogenic form, are markedly 
enriched in human atheroma. Statins inhibit isoprenylation of key NAD (P) H oxidase 
components, leading to suppression in superoxide formation in vitro. The effects of 
statins on specific oxidation pathways in vwo are not known. 
Methods: Subjects (n=35) with hypercholesterolemia and no known coronary artery dis- 
ease were evaluated at baseline and following 12 weeks of therapy (atorvastatin, IO mgl 
d). Plasma levels of protein-bound NOPTyr and diTyr were determined by mass spec- 
trometry, and compared with alterations in levels of LDL-cholesterol (LDL-C) and high 
sensitive C-reactive protein (hsCRP). 
Results: Statin therapy caused significant reductions in the content (per mg plasma pro- 
tein) of mean NOPTyr and diTyr levels that were similar in magnitude to the reductions in 
mean LDL particle number (apoE-100) and total cholesterol (29% and 25%, respectively; 
P<O.OOl each). No significant correlations were noted between statin-induced changes 
in diTyr or NOPTyr and LDL-C or CRP. 
Conclwon: Statms promote potent systemic anti-Inflammatory and antioxldant effects 
independent of their influence on LDL and CRP. 
Characteristics Baseline 12 weeks Absolute 





Dityrosineltyrosine (micromolelmole) 34 * 11 23*7 -11 (32) <O.OOl 
Nitrotyrosineityrosine (micron-role/ 15*7 11*5 -4 (25) 0.017 
mole) 
High sensitive C-reactwe protem 
(“‘g/dL) 
0.26 zt 0.23 * -0.2 (II) 0.096 
0.32 0.33 
1181-121 Does Secondary Prevention With Statins Eliminate the 
Risk of Hyperhomocysteinemia? 
Kurt R. Jensen, Jeffrey L. Anderson, Joseph B. Muhlestem, Dale G. Renlund. Benjamin 
D. Home, Tami L. Bair, Qunyu LI. Donald L. LappB, LDS Hospital, Salt Lake City, UT, 
University of Utah, Salt Lake City UT 
Background: Hyperhomocysteinemia has emerged as a graded, independent risk factor 
for atherosclerosis. The molecular mechanism of vascular injury is uncertain. In a recent 
report, HMG CoA reductase mRNA and protein were found to be unregulated in human 
umbilical vein endothelial cells in response to increasing homocysteine (HCY) concentra- 
tions. Further, high HCY was associated with increased total cellular cholesterol content, 
and slmvastatin reduced cellular cholesterol and prevented HCY-induced suppression of 
nitric oxide production. 
Methods: We tested whether the mortality benefits of HMG CoA reductase inhibitors 
(statins) would be proportionately greater among coronary artery disease (CAD) patients 
with hyperhomocysteinemla. A total of 2,470 consecutive consenting patients who under- 
went angiography, had documented CAD, had a fasting HCY measurement, and were 
prospectively entered into the Intermountain Heari Collaborative Study Registry were 
studied. Multivariable Cox regressions were performed to assess the predictive value of 
HCY, statin use, and 15 other variables for survival. 
Results: Average age was 65*11 years; 77% were men; 27% were discharged on a sta- 
tin. During 3.8+1.6 years of follow-up, 379 (9.6%) died. HCY was higher among dying 
(median, 14.6 l,tmoVL) than survwing patients (13.0 pmol/L, p<O.OOl). The adjusted haz- 
ard ratio (HR) of death for HCY tertile 3 (>15.4 pmol/L) vs. 1 (<I 1.4 pmol/L) was 1.44 
(Cl=1 .I l-l .SS,p=O.OOS). As expected, statin therapy reduced the nsk of dying (HR=0.74, 
Cl=O.45-0.96, p=O.O2). However, proportionate reductions in mortality were no greater in 
the highest (HR=0.78) or middle (HR=0.74) than the lowest HCY tertile group (H&0.68) 
(~70.7 for statin’HCY interactions). 
Conclusion: High HCY is confirmed to be an independent risk factor for patients with 
established CAD. However, HCY levels do not define patient groups with differential sur- 
viva1 responses to statin therapy. Statins are indicated equally across the range of HCY 
plasma concentrations for secondary coronary prevention. Additional specific measures 
may be indicated for hyperhomocysteinemia. 
1181-122 Statins Reduce the Incidence of Atrial Fibrillation in 
Patients With Coronary Artery Disease 
Yinong Young-X& Charles M. Blatt. Susanna Bedell, Thomas Graboys, Brian Bilchik, 
Shmuel Ravid Lown Cardiovascular Research Foundation, Brookline. MA, Harvard 
School of Public Health, Boston, MA 
Background:Atrial Fibrillation (AF) is frequently associated factors that also predispose 
patlents to the development of coronary artery disease (CAD). We hypothesized that sta- 
tin therapy might have a beneficial effect on AF prevention in patients with CAD. Meth- 
od= The study cohort included patients with chronic stable CAD followed prospectively 
wth annual questionnaires. Clinically documented AF episodes were recorded through- 
out the study. The exposure of interest was statins use. We calculated percent-annual- 
ized incidence rate and ‘estimated the odds ratios (ORs) as well as 95% confidence 
intervals (Cl). Findings 482 study subjects had mean follow-up of four years and a rnax- 
imum of seven years. A total of 130 episodes of AF occurred in 80 patients. Comparing 
the 132 patients who had continuous use of statins and 192 patients who did not use any 
cholesterol-lowering drugs, statin use was associated with lower percent-annualized inci- 
dence rate of AF (2 vs. 3.9). Comparison of the incidence rate on statin to the incidence 
rate when patients were not using statin revealed that statin use was associated with 
lower risk of having AF (OR, 0.41; 95% Cl, 0.22-0.78). This association has remained 
significant after adjustment for potential confounders such as age, hypertension, diabe- 
tes, drug usage, and medical treatments. 
Interpretations Use of statins in patients with CAD appeared protective against AF by 
an unknown mechanism independent of cholesterol level and new cardiac events. 
i 
1181-123 Additive Effects of Ramipril and Atorvastatin on 
Inflammatory Cytokines Interferon-y, Tumor Necrosis 
Factor-a, Interleukin-6, and C-Reactive Protein in 
Diabetic Patients With Congestive Heart Failure 
Linda G. Tan, Stanley A. Tan, Lee S. Berk, Linda F. Lukman, Oakcrest Health Research 
Institute, Yucaipa. CA 
Background Interferon-y (lFN-& tumor necrosis factor-a (TNF-a) and C-reactive pro- 
tein (CRP) aggravate atherosclerosis and myocardial remodeling in CHF. Interleukin-6 
(IL-6) increases CAP. Diabetic patients have increased IFN-y, TNFa. IL-6 and CRP, and 
higher incidence of CHF. Statins have been reported to decrease CRP, and ACE inhibi- 
tors regress myocardial hypertrophy in CHF. 
Objective: We compared the effects of atorvastatin (A), ramipril (R), and combination of 
A+R on IFN-/, TNFa, IL-6 and CRP in diabetic patients with CHF. 
Methods 24 diabetics (hgb A,c 7.1+1.3%) with CHF (EF<30%) were divided into two 
groups. Group A received A 40 mgld, and group R IO mgld R. At 6 mo, R was added to 
group A, and A to group R. Lipid profile and the cytokines were measured and echocar- 
diograms were performed at baseline and every 2 mo. 
Results: Basal cyiokines levels were above normal in all subjects. In group A, the LDL 
cholesterol decreased significantly at 2 mo. HDL rise and LVH regression were observed 
at 4 mo. IFN?, TNF-a & IL-6 decreased at 4 mo, and CRP at 6 mo. In group R, LVH 
regressed and EF improved significantly at 4 mo. IFN?: TNF-a and IL-6 decreased at 2 
mo, and CRP at 4 mo. The magnitude of cytokines decreases were comparable in both 
group A & R. When R was added to group A, and A to group R, additive cytokine drops 
occurred. No significant changes in HDL, LDL, and total cholesterol were seen in group 
R. A lowered LDL cholesterol and increased HDL when added to group R, but no further 
improvement in CHF was noted. R significantly improved CHF and regressed LVH when 
added to group A. 
Conclusions Both A and R lower IFNy, TNF-a, IL-6 and CRP, and their effects are 
additive when combined. A lowers LDL and increases HDL, but only minlmalty improves 
CHF. R is a more potent LVH reducer and EF enhancer, but does not effect lipids. A+R 
are additive in lowering cytokines, potent lipid lowering agent, LVH reducer and EF 
enhancer. Thus combined atorvastatin and ramipril therapy can be beneficial for diabetic 
oatients with CHF. 
